Previous 10 | Next 10 |
Gainers: Celyad (NASDAQ:CYAD) +35%. Longeveron (NASDAQ:LGVN) +29%. Marvell Technology (NASDAQ:MRVL) +18%. Petros Pharmaceuticals (NASDAQ:PTPI) +17%. CTI BioPharma (NASDAQ:CTIC) +16%. Tilly's (NYSE:TLYS) +14%. Krispy Kreme (NASDAQ:DNUT) +10%. PetIQ (NASDAQ:PETQ) +9%. Vicinity (NASDAQ:VEV) +9%....
Gainers: Celyad Oncology CYAD +41%, Longeveron LGVN +28%, Petros Pharmaceuticals (NASDAQ:PTPI) +26%, AirSculpt Technologies AIRS +12%, Werewolf Therapeutics (NASDAQ:HOWL) +12%. Losers: Esperion Therapeutics ESPR -40%, Biofrontera (NASDAQ:...
Esperion (NASDAQ:ESPR) has priced its public offering of ~32.1M shares of common stock and short-term warrants to purchase up to equal number of shares. Each common share is being sold together with one warrant at a combined price of $7.00/share, for expected gross proceeds of ~$225M. Underwr...
ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced the pricing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and short-term warrants to pur...
Esperion (NASDAQ:ESPR) has slipped 13.15% in after-hours trading on announcing a proposed public offering of its common stock and warrants to purchase shares of common stock. Terms of the offering are yet to be determined. The underwriter may be granted a 30-day option to purchase a...
ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock (or common stock equivalents in l...
Gainers: Biofrontera (NASDAQ:BFRI) +154%. Longeveron (NASDAQ:LGVN) +79%. Ocuphire Pharma (NASDAQ:OCUP) +36%. Society Pass (NASDAQ:SOPA) +24%. Biofrontera (NASDAQ:BFRA) +23%. Better Therapeutics (NASDAQ:BTTX) +20%. Applied UV (NASDAQ:AUVI) +19%. Standard Lithium (NYSE:SLI) +19%. Blue Star Food...
Gainers: MediciNova (NASDAQ:MNOV) +27%. Puma Biotechnology (NASDAQ:PBYI) +6%. GoHealth (NASDAQ:GOCO) +5%. Chindata Group Holdings Limited (NASDAQ:CD) +4%. Nutanix (NASDAQ:NTNX) +4%. Losers: Autodesk (NASDAQ:ADSK) -13%. Esperion Therapeutics (NASDAQ:ESPR) -10%. Cl...
During the semi-annual review, Clovis Oncology (CLVS -1.1%), 22nd Century Group (XXII -1.2%), Verastem (VSTM +8.7%), Omeros (OMER -0.7%), Therapeutics MD (TXMD -3.2%), CEL-SCI (CVM +2.1%), ZIOPHARM Oncology (ZIOP -1.9%), Karyopharm Therapeutics (KPTI +1.1%), Esperion Therapeutics (E...
- Analysis of pooled Phase 3 data showed that NEXLETOL [bempedoic acid ( BA)] alone lowered LDL-C levels comparable to that of a moderate- or high-intensity statin (≥ 30%) in nearly 1 out of 3 of patients - - In patients with metabolic syndrome NEXLETOL lowered hemogl...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...
– OMERS Life Sciences to Purchase Esperion’s European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment – – Esperion Retains Rights to Receive all Poten...